Executives On The Move: Changes to Development Posts At Amgen, Orchard Therapeutics, Tilray, Genentech And NGM Biopharma
It’s all about development — Amgen Development VP now CTO at rare disease firm Orchard Therapeutics, and Goldman Sachs exec is chief corporate development officer at pharma/cannabis business Tilray. Meanwhile, Genentech early clinical development VP switches to CMO spot at cardio-metabolic and liver disease company NGM Biopharma.
You may also be interested in...
Executives On The Move: Comings And Goings At JSC Olainfarm And MorphoSys, Plus A Promotion At Twist Bioscience
Latvian pharma producer JSC Olainfarm picks next CEO and chairman, and CSO is scheduled to depart German therapeutic antibody company MorphoSys. Meanwhile, synthetic DNA manufacturer Twist Bioscience promotes SVP to chief commercial officer.
Executives On The Move: A Finance And Development Change At EyePoint Pharma And Exits At PPD And Novartis
Ophthalmology biopharma EyePoint Pharmaceuticals confirms its new CFO and head of corporate development. A former PPD med director is now CMO of vaccine developer ILiAD Biotechnologies and neurological disorders firm Ovid Therapeutics adds ex-Novartis VP as chief commercial officer.
Executives On The Move: Teva Pharma Picks A CFO, Ipsen Decides On An R&D Position And Bavarian Nordic Names Its Commercial Hire
Teva Pharmaceuticals now has a new EVP, CFO. Ipsen Group decides on a former Shire Pharma CMO for Head, R&D and Bavarian Nordic names a vaccines commercial leader from GSK to be Chief Commercial Officer in 2020.